Monday, December 16, 2024
Facebook Linkedin Twitter
HomeTagsMoleculin

Moleculin

Healthcare

Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid...

News Desk -
Moleculin Biotech, Inc, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced the first...
Biotechnology

Moleculin Receives FDA Orphan Drug Designation of WP1122

PR Newswire -
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced that the...
Biotechnology

Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

PR Newswire -
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported preliminary results...
Biotechnology

Moleculin Provides Annamycin AML Program Update and Outlines

PR Newswire -
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced preliminary results...
Biotechnology

Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

PR Newswire -
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported preliminary interim...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us